Finanzen von KALA BIO Inc (KALA)KALAKALA BIO Inc

Evaluating the bottom line, KALA BIO Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -345.32%, provide a clear picture of how effectively KALA converts its operational activities into shareholder value.

In the context of the broader market, KALA competes directly with industry leaders such as GTBP and MBRX. With a market capitalization of $13.35M, it holds a significant position in the sector. When comparing efficiency, KALA's gross margin of N/A stands against GTBP's N/A and MBRX's N/A. Such benchmarking helps identify whether KALA BIO Inc is trading at a premium or discount relative to its financial performance.

KALA BIO has reported significant losses, with a net income of -8,950,000 USD in Q3 2024 and a forward P/E ratio of 0, indicating no earnings expected in the near term. The company's current ratio is high at 7.91 in Q1 2026, suggesting good short-term liquidity, but the overall financial health is concerning with a debt to equity ratio of 0% in recent quarters.